Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
VT VTRS Viatris Inc FY ended Feb 23, 2026 | $16.34 | $18.77B | $30.17B | $14.30B | -$469.30M | -$3.51B | -5.45x | 1.31x | 1294.87x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.76 | $3.61B | $13.79B | $6.22B | $1.29B | $187.00M | 19.11x | 0.58x | 10.69x |
TE TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD FY ended Dec 31, 2025 | $36.44 | $42.46B | $63.85B | $17.26B | $3.15B | $1.41B | 30.12x | 2.46x | 15.58x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 340.42x | 4/5 | $63.32B | $2,815.25 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 1.67x | 5/5 | $1.48B | $65.69 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -4.39x | 5/5 | -$343.68M | — | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
VT VTRS Viatris Inc FY ended Feb 23, 2026 | $16.34 | $18.77B | $30.17B | $14.30B | -$469.30M | -$3.51B | -5.45x | 1.31x | 1294.87x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.76 | $3.61B | $13.79B | $6.22B | $1.29B | $187.00M | 19.11x | 0.58x | 10.69x |
TE TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD FY ended Dec 31, 2025 | $36.44 | $42.46B | $63.85B | $17.26B | $3.15B | $1.41B | 30.12x | 2.46x | 15.58x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 340.42x | 4/5 | $63.32B | $2,815.25 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 1.67x | 5/5 | $1.48B | $65.69 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -4.39x | 5/5 | -$343.68M | — | Peer averages are not economically meaningful for this method. |
